Trial · NCT02344628
Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
NCT02344628, Phase 3, Completed, London School of Hygiene and Tropical Medicine; results first posted 2018-10-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Two Different Doses of Azithromycin for Treatment of Yaws. Trials, record NCT02344628. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02344628
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
- NCT number
- NCT02344628
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 583 participants, actual
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Conditions
- Yaws
- Interventions
- Azithromycin
- First posted
- 2015-01-26
- Last updated
- 2018-10-31
- Results first posted
- 2018-10-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Clinical and Serological Cure | 6 Months | Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws. |
| Secondary | Number of Participants With Clinical and Serological Cure in Latent Yaws | 6 Months | Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative. |
| Secondary | Number of Participants With Adverse Events | 6 months | To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinical and Serological Cure | 6 Months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Clinical and Serological Cure in Latent Yaws | 6 Months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Adverse Events | 6 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical and Serological Cure | AZT30 | 68 | Participants | ||
| Number of Participants With Clinical and Serological Cure | AZT20 | 61 | Participants | ||
| Number of Participants With Clinical and Serological Cure in Latent Yaws | AZT30 | 65 | Participants | ||
| Number of Participants With Clinical and Serological Cure in Latent Yaws | AZT20 | 73 | Participants | ||
| Number of Participants With Adverse Events | AZT30 | 12 | Participants | ||
| Number of Participants With Adverse Events | AZT20 | 14 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AZT30 | 291 | |
| Overall Study | STARTED | AZT20 | 292 | |
| Overall Study | COMPLETED | AZT30 | 200 | |
| Overall Study | COMPLETED | AZT20 | 206 | |
| Overall Study | NOT COMPLETED | AZT30 | 91 | |
| Overall Study | NOT COMPLETED | AZT20 | 86 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Discomfort | Gastrointestinal disorders | AZT30 | 3 | 291 | |
| other | Abdominal Discomfort | Gastrointestinal disorders | AZT20 | 6 | 292 | |
| other | Diarrhoea | Gastrointestinal disorders | AZT30 | 2 | 291 | |
| other | Diarrhoea | Gastrointestinal disorders | AZT20 | 2 | 292 | |
| other | Dizziness | Nervous system disorders | AZT30 | 2 | 291 | |
| other | Dizziness | Nervous system disorders | AZT20 | 4 | 292 | |
| other | Headache | Nervous system disorders | AZT30 | 2 | 291 | |
| other | Headache | Nervous system disorders | AZT20 | 0 | 292 | |
| other | Itching | Skin and subcutaneous tissue disorders | AZT30 | 0 | 291 | |
| other | Itching | Skin and subcutaneous tissue disorders | AZT20 | 2 | 292 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AZT30 | ||
| Total, all-cause mortality | AZT20 | ||
| Total, other adverse events | AZT30 | 12 | 291 |
| Total, other adverse events | AZT20 | 15 | 292 |
| Total, serious adverse events | AZT30 | 0 | 291 |
| Total, serious adverse events | AZT20 | 0 | 292 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29456191 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| AZT30 vs AZT20: Number of Participants With Clinical and Serological Cure in Latent Yaws | Trial comparisons |
| AZT30 vs AZT20: Number of Participants With Clinical and Serological Cure | Trial comparisons |
| AZT30 vs AZT20: Number of Participants With Adverse Events | Trial comparisons |
| AZT30 vs AZT20: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02344628
GET https://conductscience.org/api/trials/v1/NCT02344628/registered